Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PETTA, Salvatore
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.296
EU - Europa 4.795
AS - Asia 1.511
SA - Sud America 24
AF - Africa 20
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 15
Totale 23.677
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.258
IT - Italia 1.947
CN - Cina 1.185
FI - Finlandia 721
UA - Ucraina 383
DE - Germania 378
IE - Irlanda 366
GB - Regno Unito 296
RU - Federazione Russa 176
RO - Romania 130
SE - Svezia 119
FR - Francia 86
IN - India 66
KR - Corea 65
BE - Belgio 56
HK - Hong Kong 56
TR - Turchia 51
CA - Canada 29
IR - Iran 23
NL - Olanda 23
CH - Svizzera 20
DK - Danimarca 19
JP - Giappone 15
AT - Austria 13
EG - Egitto 13
BG - Bulgaria 12
AU - Australia 11
CL - Cile 11
ES - Italia 11
EU - Europa 10
GR - Grecia 10
PL - Polonia 10
MX - Messico 9
CZ - Repubblica Ceca 7
UZ - Uzbekistan 7
PH - Filippine 6
SG - Singapore 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BR - Brasile 5
NZ - Nuova Zelanda 5
VN - Vietnam 5
AR - Argentina 3
ID - Indonesia 3
NO - Norvegia 3
PE - Perù 3
PK - Pakistan 3
SA - Arabia Saudita 3
TH - Thailandia 3
BF - Burkina Faso 2
HR - Croazia 2
IL - Israele 2
LB - Libano 2
MY - Malesia 2
NG - Nigeria 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CO - Colombia 1
EC - Ecuador 1
HU - Ungheria 1
IQ - Iraq 1
KZ - Kazakistan 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
PT - Portogallo 1
RS - Serbia 1
Totale 23.677
Salva come PNG Salva come JPEG
Città #
Fairfield 3.120
Ashburn 1.708
Woodbridge 1.495
Chandler 1.359
Seattle 1.226
Houston 1.195
Wilmington 1.162
Cambridge 1.079
Ann Arbor 715
Palermo 487
Medford 440
Des Moines 370
Dublin 365
Altamura 340
Princeton 278
Lawrence 255
Nanjing 252
Jacksonville 212
San Diego 162
Boardman 126
New York 124
Beijing 112
Jinan 93
Ludwigshafen am Rhein 91
Shenyang 85
Dearborn 84
Milan 79
Tulsa 76
Nanchang 74
Hebei 69
London 68
Changsha 65
Jiaxing 62
Tianjin 56
Zhengzhou 56
Brussels 55
Izmir 45
Saint Petersburg 44
San Paolo di Civitate 44
Seongnam 44
Redwood City 41
Rome 40
Central 36
Ningbo 35
Falls Church 32
Hangzhou 30
Kumar 30
Los Angeles 29
Taizhou 28
Bremen 27
Venice 25
Chicago 23
Orange 23
Lanzhou 22
Guangzhou 21
Phoenix 20
Washington 20
Kilburn 18
Pune 18
Verona 18
Haikou 17
Helsinki 17
Ottawa 17
Hong Kong 16
Tappahannock 14
Taiyuan 13
Auburn Hills 12
Bari 12
Fuzhou 12
Hounslow 12
Norwalk 11
Aragona 10
Hefei 10
San Mateo 10
Sofia 10
Tehran 10
Indiana 9
Redmond 9
Seoul 9
Cairo 8
Messina 8
Munich 8
Naples 8
West Jordan 8
Amsterdam 7
Kunming 7
Lappeenranta 7
Shanghai 7
Southwark 7
Wandsworth 7
Barcellona Pozzo di Gotto 6
Bologna 6
Castellammare Di Stabia 6
Catania 6
Düsseldorf 6
Edinburgh 6
Esslingen am Neckar 6
Frankfurt Am Main 6
Moscow 6
Mussomeli 6
Totale 18.680
Salva come PNG Salva come JPEG
Nome #
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 199
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 190
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 189
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 188
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 182
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 180
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 179
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 177
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 174
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 168
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 165
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 165
The Hepatic Expression of Vitamin D Receptor is Inversely Associated with the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. 164
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 163
The cheating liver: imaging of focal steatosis and fatty sparing 162
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 159
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 154
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS 153
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 150
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 149
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 149
MERTK rs4374383 polymorphism affects the severity of fibrosis in nonalcoholic fatty liver disease 149
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver 148
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 145
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 143
Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study 143
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women 142
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 142
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 141
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis 141
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 139
STORIA NATURALE DELLA CIRROSI EPATICA 138
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 136
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 136
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 136
Metabolic Factors and Chronic Hepatitis C: A Complex Interplay 135
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 134
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 133
Genetic background in nonalcoholic fatty liver disease: A comprehensive review 133
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 133
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 133
Hyperuricemia in non-alcoholic fatty liver disease: authors' reply. 132
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 131
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 130
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. 129
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 129
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 129
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. 128
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 128
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients 127
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 126
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 126
The presence of White Matter Lesions is not associated with Non-alcoholic Fatty Liver Disease but with its histological severity 125
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 125
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. 125
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 124
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 124
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 124
Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe? 123
Role of myeloid-epithelial-reproductive tyrosine kinase and macrophage polarization in the progression of atherosclerotic lesions associated with nonalcoholic fatty liver disease 123
Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. 121
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C 121
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 121
Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies 121
Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients". 120
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 120
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent 120
An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers 120
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 120
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 120
Hepatic expression of cyclooxygenase-2 in non alcoholic fatty liver disease 119
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C 119
Diet, Weight Loss, and Liver Health in NAFLD: Pathophysiology, Evidence and Practice 119
Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD 119
Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity 119
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 119
Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values 118
Statin use and non-alcoholic steatohepatitis in at risk individuals 117
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis 117
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 117
Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. 115
Cardiovascular diseases and HCV infection: a simple association or more? 115
Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with Nonalcoholic fatty liver disease 115
Hepatitis C virus and cardiovascular: A review 115
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 115
Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 114
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 114
Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model 113
Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients 113
TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. 112
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C 112
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. 111
Is liver stiffness measurement unreliable in obese patients? authors' reply. 111
Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease 111
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study 110
FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage 110
Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: spectators or actors? 109
Can we prevent and modify cardiometabolic disorders by controlling HCV infection? 109
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives 109
LIPIDOMICS OF FATTY LIVER IN NAFLD AND HCV INFECTION: LIVER SPHYNGOLIPIDS AND FATTY ACIDS 108
Totale 13.375
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.661
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.661
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.393 0 0 0 0 0 0 0 0 0 0 720 673
2019/20206.911 644 260 292 656 697 928 756 564 823 364 735 192
2020/20214.035 238 308 320 368 269 195 214 300 344 621 486 372
2021/20223.291 165 562 119 92 75 150 145 348 392 387 248 608
2022/20234.474 497 949 80 430 418 652 315 333 465 44 208 83
2023/20241.763 79 293 113 138 170 517 240 108 31 63 11 0
Totale 25.186